Tagrisso + Orpathys Hits Both PFS and OS Endpoints in Phase III SAFFRON Trial
AZN is trading near its 52-week low of $141.772 (11% above the low).
Summary
AstraZeneca's Tagrisso plus Orpathys combination demonstrated statistically significant improvements in both progression-free and overall survival in the Phase III SAFFRON trial for MET-driven EGFR-mutated lung cancer after progression on Tagrisso.
Key Events · Product Development and Regulatory · AZN
-
SAFFRON Trial Meets Both Endpoints
Tagrisso plus Orpathys showed statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in 338 patients with MET-driven EGFRm NSCLC after progression on Tagrisso.
-
First Global Phase III Win in Setting
This is the first global Phase III trial to show significant PFS and OS benefits in MET-driven EGFRm NSCLC after progression on a third-generation EGFR-TKI, addressing a population with poor outcomes and no biomarker-directed oral treatment options.
-
Regulatory Path Forward
Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities, supporting potential global registrations of the Tagrisso plus Orpathys combination.
-
Safety Profile Consistent
The safety profile was consistent with the known profiles of each medicine, with no new safety findings reported.
Analysis · AZN · Life Sciences
The SAFFRON Phase III trial met both progression-free survival and overall survival endpoints for the Tagrisso plus Orpathys combination in MET-driven EGFR-mutated lung cancer after progression on Tagrisso. This is the first global Phase III trial to show significant PFS and OS benefits in this setting, addressing a major unmet need where one in three patients develop MET overexpression or amplification. The positive results reinforce Tagrisso as the backbone therapy across EGFRm lung cancer and support global regulatory submissions for the combination.
At the time of this filing, AZN was trading at $156.81 on NYSE in the Life Sciences sector, with a market capitalization of approximately $242.6B. The 52-week trading range was $141.77 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.